Localized, targeted, and sustained siRNA delivery
Melissa D Krebs1, Eben Alsberg
1Case Western Reserve University, Biomedical Engineering, 309 Wickenden, 10900 Euclid Avenue, Cleveland, OH, USA.
Abstract:
Short interfering RNA (siRNA) functions directly in the cytoplasm, where it is assembled into an RNA-induced silencing complex (RISC). The localized delivery of siRNA to a specific site in vivo is highly challenging. There are many disease states in which a systemic effect of RNAi may be desirable; some examples include non-localized cancers, HIV, neurodegenerative diseases, respiratory viruses, and heart and vascular disease. In this Concept, we will focus on the localized delivery of siRNA to a target site using various delivery modalities. In certain tissues, such as the eye, central nervous system and lung, it has been demonstrated that a simple injection of naked siRNA will silence gene expression specifically in that tissue. To achieve local gene silencing in other tissues, a variety of approaches have been pursued to help stabilize the siRNA and facilitate uptake; they include chemical modification of the siRNA or complexation within liposomes or polymers to form nanoparticles. Recently, the use of macroscopic biomaterial scaffolds for siRNA delivery has been reported, and although there is still significant work to be done in this area to optimize the delivery systems, it is an important area of research that offers the potential for having great impact on the field of siRNA delivery.
Insights
Localized delivery of short interfering RNA (siRNA) is crucial for treating various diseases. Researchers are exploring diverse methods, including nanoparticles and biomaterial scaffolds, to enhance siRNA
Area of Science:
- Molecular Biology
- Biotechnology
- Drug Delivery Systems
Background:
- Short interfering RNA (siRNA) is a molecule that silences gene expression within the cytoplasm by forming an RNA-induced silencing complex (RISC).
- Effective localized delivery of siRNA in vivo remains a significant challenge across numerous disease states, including cancers, HIV, neurodegenerative disorders, and cardiovascular diseases.
Purpose of the Study:
- To explore and evaluate various modalities for the localized delivery of siRNA to specific target sites.
- To review current strategies and emerging approaches for overcoming challenges in siRNA delivery for therapeutic applications.
Main Methods:
- Direct injection of naked siRNA into specific tissues like the eye, central nervous system, and lung.
- Chemical modification of siRNA to improve stability and cellular uptake.
- Complexation of siRNA with liposomes or polymers to create nanoparticles for enhanced delivery.
- Utilizing macroscopic biomaterial scaffolds as a novel approach for localized siRNA delivery.
Main Results:
- Naked siRNA injection has demonstrated successful gene silencing in specific tissues (eye, CNS, lung).
- Chemical modifications and nanoparticle formulations (liposomes, polymers) show promise in stabilizing siRNA and facilitating uptake in other tissues.
- Biomaterial scaffolds represent a recent and developing area for localized siRNA delivery, requiring further optimization.
Conclusions:
- Localized siRNA delivery is essential for treating a range of systemic diseases.
- A variety of methods, including direct injection, chemical modification, nanoparticles, and biomaterial scaffolds, are being investigated to improve siRNA delivery efficacy.
- Further research into optimizing these delivery systems, particularly biomaterial scaffolds, holds significant potential for advancing RNAi-based therapeutics.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...